Navigation Links
Interpreting the Avastin-Lucentis study for persons with macular degeneration

Clarksburg, MDThis week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known as Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat the wet form of AMD, were similarly effective in maintaining vision.

In this clinical trial funded by the National Eye Institute (NEI) of the National Institutes of Health, CATT researchers found that two years into the study, two-thirds of patients retained a vision of 20/40 or better, whereas only 15% of patients retained similar vision with previous treatments.

"As a nonprofit organization that funds groundbreaking research and provides public information on AMD, the American Health Assistance Foundation welcomes discoveries from the CATT trials on wet AMD, which affects two million Americans," says AHAF Vice President for Scientific Affairs, Guy Eakin, Ph.D. "We also call for more support of research on this and other eye diseases. In the future, our goals are not just to maintain vision, but to restore vision and ultimately to prevent the disease entirely."

For both drugs, vision was slightly better with monthly injections, rather than with less frequent or "as-needed" injections. However, study authors were also quick to note that since as-needed dosing requires fewer drug injections into the eye, some patients, following consultation with their eye doctor, may elect not to choose monthly injections, balancing relative risks and cost.

"While this study neither adds nor removes the number of drug choices available to the eye care provider, it does facilitate better informed decision making between the doctor and patient," says Eakin. He notes the findings of study authors, who conclude, "The choice of drug and dosing regimen for patients must balance the comparable effects on vision, the possibility of true differences in adverse events, and the 40-fold difference in cost between [Lucentis and Avastin]."

AMD is the leading cause of irreversible central vision loss in people older than age 60. The disease affects the central area of the retina known as the macula, and, without treatment, gradually destroys the central vision needed to conduct many activities of daily living. Although vision loss from AMD cannot be reversed at present, early detection and treatment can halt the progression of the disease.

In the wet form of AMD, Avastin and Lucentis, two therapies known as angiogenesis inhibitors, block the growth of abnormal blood vessels and fluid leakages that damage the eye. Lucentis was approved for AMD treatment by the FDA in 2006; Avastin is approved for other purposes but has been used "off-label" to treat AMD. Both are manufactured by Genentech, and Lucentis is significantly more expensive that Avastin.

"AMD patients should note that serious adverse eventsinvolving the development or worsening of medical conditionsoccurred at a 40% rate for Avastin and a 32% rate for Lucentis," adds Eakin. "However, the study authors note that CATT was not capable of determining whether there was an association between a particular adverse event and treatment. The median age of CATT patients was older than 80, and certain medical conditions are more common to elderly populations. AMD patients should discuss the risk of adverse events with their eye doctor."

"While we welcome the latest information from the CATT study, AHAF urges even more public and privately funded research on AMD," notes Eakin. "This is particularly true for the more common dry form of AMD affecting nine million Americans, for which there are no approved treatment options at present."

The drugs reviewed in the CATT study focus only on the growth of blood vessels in the wet form of the disease. Says Eakin, "We need to target other aspects of the disease, like inflammation and protection of neurons. We also need a stronger national commitment to funding eye research and to improving the lives of people affected by or vulnerable to AMD and other blinding eye diseases."


Contact: Alice Kirkman
AHAF-American Health Assistance Foundation

Related medicine news :

1. LifeLinks Revolutionizes Video Interpreting, Shows Spanish Interpreting in Added Dimension-VIDEO!
2. SOS Talk a New Way of Telephone Interpreting Serving the Globe, No Reservation or Start-Up Cost, Just Pay as You Go
3. Pediatric cardiologists not always accurate in interpreting ECG results for young athletes
4. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
5. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
6. TV drama can be more persuasive than news program, study finds
7. Study carried out into biological risks of eating reptiles
8. Neuroimaging study may pave way for effective Alzheimers treatments
9. Study finds racial gaps continue in heart disease awareness
10. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
11. First blinded study of venous insufficiency prevalence in MS shows promising results
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The ... waive paid entry and parking fees at several of their most popular properties, ... Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage ...
(Date:11/24/2015)... ... November 24, 2015 , ... In response to recent news ... deaths from prescription opioids in the United States grew 400 percent between 1999 and ... opioids were involved in 37 percent of all fatal drug overdoses. (1) , While ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, ... at a live taping of the next CURE Connections® video series ... Cancers 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the ... safety tips to help protect your family and vehicle. , According to the National ... Thanksgiving holiday weekend. Amica is sharing the following safety tips from the NHTSA: ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Figure 1, a free mobile-first network ... cases, has launched a new completely redesigned web version ... allows radiologists, who work primarily on a desktop, to ... with its radiologist user base, Figure 1 is hosting ... North America (RSNA) Annual Meeting. ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
Breaking Medicine Technology: